Stephanie Holland

Conference Coverage

Adjuvant Pembrolizumab Improved Disease-Free Survival Among Patients With Muscle-Invasive Bladder Cancer

01/26/2024

Interim DFS/OS results from the phase 3 AMBASSADOR Alliance AO31501 study demonstrated adjuvant pembrolizumab improved DFS among patients with high-risk muscle-invasive urothelial carcinoma.

Interim DFS/OS results from the...

01/26/2024

Oncology

News

Predicting PD-L1 Expression in Non-Small Cell Lung Cancer With Machine Learning Tool

09/11/2023

Stephanie Holland ;

According to results of a performance comparison, a machine learning tool built using clinical and radiological features can predict PD-L1 expression in NSCLC prior to neoadjuvant treatment when indeterminable by biopsy.

According to results of a...

09/11/2023

Oncology

Conference Coverage

Endocrine Therapy Predominant Therapeutic Option in HR+/HER2-Negative Advanced Breast Cancer

06/17/2022

Stephanie Holland ;

According to a retrospective cohort analysis, endocrine therapy in the first-line was found to be the predominant therapeutic option for hormone receptor-positive HER2-negative advanced breast cancer.

According to a retrospective...

06/17/2022

Oncology

News

Addition of Canakinumab to First-Line Pembrolizumab Plus Chemotherapy Did Not Prolong Survival Outcomes Among Patients With Advanced/Metastatic Non-Small Cell Lung Cancer

01/09/2024

Stephanie Holland ;

According to results from the CANOPY-1 trial, the addition of canakinumab to first-line pembrolizumab plus chemotherapy did not prolong PFS or OS among patients with advanced or metastatic non-small cell lung cancer who do not harbor ALK or...

According to results from the...

01/09/2024

Oncology

News

Relacorilant Plus Nab-Paclitaxel Improved Survival, Response in Platinum-Resistant Ovarian Cancer

07/25/2023

Stephanie Holland ;

According to results of a phase 2 trial, intermittent relacorilant plus nab-paclitaxel improved PFS, DOR, and OS with similar ORR to that of nab-paclitaxel monotherapy among patients with pre-treated, recurrent, platinum-resistant ovarian...

According to results of a phase...

07/25/2023

Oncology

News

Rechallenge With Olaparib Maintenance Improved PFS Among Patients With Previously Treated, Platinum-Sensitive Ovarian Cancer

10/10/2023

Stephanie Holland ;

Results from the OReO/ENGOT-ov38 trial demonstrated that rechallenging with olaparib in the maintenance setting improved progression-free survival among patients with previously treated, platinum-sensitive ovarian cancer, regardless of BRCA...

Results from the OReO/ENGOT-ov38...

10/10/2023

Oncology

News

Trabectedin Did Not Improve Survival or Safety Among Patients With Recurrent Ovarian Cancer and BRCA-Mutation/BRCAness Phenotype

02/09/2024

Stephanie Holland ;

Results from the phase 3 MITO-23 study demonstrated trabectedin did not improve overall survival and showed a worse safety profile compared to standard chemotherapy among patients with recurrent ovarian cancer and BRCA-mutation/BRCAness...

Results from the phase 3 MITO-23...

02/09/2024

Oncology

News

Addition of Camrelizumab to Neoadjuvant Chemotherapy Significantly Improved Response Rate Among Patients With Resectable, Stage IIIA-IIIB NSCLC

08/10/2023

Stephanie Holland ;

According to findings from the phase 2 TD-FOREKNOW trial, adding camrelizumab to neoadjuvant chemotherapy significantly improved complete reseponse rate compared to chemotherapy alone among patients with stage IIIA to IIIB NSCLC.

According to findings from the...

08/10/2023

Oncology

Sunvozertinib Demonstrates Superior Antitumor Efficacy Over Current Available Therapy for NSCLC With EGFR Exon20 Insertion Mutations

06/19/2023

Stephanie Holland ;

Results from the phase 2 WU-KONG6 study demonstrate superior antitumor efficacy with sunvozertinib in pretreated patients with NSCLC and EGFR exon20 insertion mutations when compared to current available therapies.

Results from the phase 2...

06/19/2023

Oncology

News

Perioperative Durvalumab Added to Neoadjuvant Chemotherapy Increased Survival, Response Among Patients With Resectable Non-Small Cell Lung Cancer

12/06/2023

Stephanie Holland ;

Results from a randomized study demonstrated perioperative durvalumab added to neoadjuvant chemotherapy significantly increased event-free survival (EFS) and pathological complete-response compared to chemotherapy alone among patients with...

Results from a randomized study...

12/06/2023

Oncology